Cargando…
Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness
Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD. More clinical trials on suPAR is in the future research agenda.
Autores principales: | Cyrille, Nicole B., Villablanca, Pedro A., Ramakrishna, Harish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900352/ https://www.ncbi.nlm.nih.gov/pubmed/27052059 http://dx.doi.org/10.4103/0971-9784.179588 |
Ejemplares similares
-
Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease
por: Goodchild, Traci T., et al.
Publicado: (2022) -
2021 Update for the Diagnosis and Management of Acute Coronary Syndromes for the Perioperative Clinician
por: Kunkel, Katherine J., et al.
Publicado: (2022) -
Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022) -
Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017) -
Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)